Zacks.com on MSN

Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026?

Mirum's Livmarli sales surge 70% in the first nine months of 2025. Expanding approvals and commercialization are set to fuel revenue momentum into 2026.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novan (NOVN), Avidity Biosciences (RNA) and Insmed (INSM)

According to TipRanks.com, Divan is a 5-star analyst with an average return of 10.3% and a 55.4% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, ...
Investor's Business Daily on MSN

BioMarin soars 18% after folding in the $4.8 billion takeover of Amicus

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its ...

H.C. Wainwright Sticks to Its Buy Rating for Biomea Fusion (BMEA)

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.